How PI3K‑gamma controls antibody production
Orchestration of the antibody response by PI3K-gamma
['FUNDING_R01'] · YALE UNIVERSITY · NIH-11330678
Researchers will examine how the protein PI3K‑gamma helps B cells make IgG antibodies, which could matter for people with antibody deficiency and recurrent infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11330678 on ClinicalTrials.gov |
What this research studies
You would hear that the team is following up on people found to have PI3K‑gamma problems that cause low antibody levels and repeat lung and sinus infections. Most work will be done in the lab using mouse models and B cells to map the step‑by‑step signals that let B cells become IgG‑producing cells. The project has three parts: defining what PI3K‑gamma does inside B cells, figuring out what turns PI3K‑gamma on during B cell activation, and testing whether changing PI3K‑gamma signals alters antibody production. Findings will be used to link the lab results back to the human immune problems previously seen.
Who could benefit from this research
Good fit: People with low IgG levels, recurrent sinopulmonary infections, or a known mutation affecting PI3K‑gamma would be the most directly relevant group.
Not a fit: Those whose immune problems come from unrelated causes (for example, non‑B cell immune defects) or healthy individuals are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, the work could point to new ways to boost antibody production or guide treatments for people with antibody deficiencies and recurrent infections.
How similar studies have performed: Recent reports of human PI3K‑gamma deficiency already showed defective antibody responses, but the detailed mechanisms remain new and are being worked out in animal and cell models.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LUCAS, CARRIE L. — YALE UNIVERSITY
- Study coordinator: LUCAS, CARRIE L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.